About | Contact Us | Register | Login
ProceedingsSeriesJournalsSearchEAI
Wireless Mobile Communication and Healthcare. 10th EAI International Conference, MobiHealth 2021, Virtual Event, November 13–14, 2021, Proceedings

Research Article

The Case for Symptom-Specific Neurological Digital Biomarkers

Download(Requires a free EAI acccount)
2 downloads
Cite
BibTeX Plain Text
  • @INPROCEEDINGS{10.1007/978-3-031-06368-8_16,
        author={John Michael Templeton and Christian Poellabauer and Sandra Schneider},
        title={The Case for Symptom-Specific Neurological Digital Biomarkers},
        proceedings={Wireless Mobile Communication and Healthcare. 10th EAI International Conference, MobiHealth 2021, Virtual Event, November 13--14, 2021, Proceedings},
        proceedings_a={MOBIHEALTH},
        year={2022},
        month={6},
        keywords={Digital biomarkers Neurocognitive assessment Mobile app Parkinson’s disease},
        doi={10.1007/978-3-031-06368-8_16}
    }
    
  • John Michael Templeton
    Christian Poellabauer
    Sandra Schneider
    Year: 2022
    The Case for Symptom-Specific Neurological Digital Biomarkers
    MOBIHEALTH
    Springer
    DOI: 10.1007/978-3-031-06368-8_16
John Michael Templeton1,*, Christian Poellabauer2, Sandra Schneider1
  • 1: University of Notre Dame, Notre Dame
  • 2: Florida International University, Miami
*Contact email: jtemplet@nd.edu

Abstract

Digital biomarkers provide novel and objective assessment of neurodegenerative diseases, such as Parkinson’s Disease (PD). This paper demonstrates that objective digital biomarkers, obtained from mobile-based functional assessments, can be used for symptom-specific insights on neurological deficiencies. These digital biomarkers were found to be sensitive to change in relation to structured physical interventions. In this pilot study, 54 participants (n = 36 PD; n = 18 control) completed 13 neurocognitive functional tasks with 115 digital biomarkers being identified and compared between groups for objective assessment, evaluation, and monitoring of disease progression. 36 (31.30%) of these biomarkers were significant ((p < 0.10)) between groups. Of the 36 significant biomarkers, 10 were motor, 6 were memory, 1 was speech, 6 were executive function, and 13 were multi-functional. 8 biomarkers were significant ((p < 0.10)) between groups regardless of intervention, which may indicate strong biomarkers to assess PD. Further, 15 (13.04%) digital biomarkers showed significance ((p < 0.10)) in relation to structured physical intervention. Overall, mobile-based digital biomarkers provide promising measures and sensitivity to functional change that can be used in assessment and monitoring of Parkinson’s Disease. Further integration of mobile device capabilities can enhance the understanding of how neurodegenerative diseases present and aid clinicians in the diagnosis and monitoring of conditions.

Keywords
Digital biomarkers Neurocognitive assessment Mobile app Parkinson’s disease
Published
2022-06-07
Appears in
SpringerLink
http://dx.doi.org/10.1007/978-3-031-06368-8_16
Copyright © 2021–2025 ICST
EBSCOProQuestDBLPDOAJPortico
EAI Logo

About EAI

  • Who We Are
  • Leadership
  • Research Areas
  • Partners
  • Media Center

Community

  • Membership
  • Conference
  • Recognition
  • Sponsor Us

Publish with EAI

  • Publishing
  • Journals
  • Proceedings
  • Books
  • EUDL